CLN2 disease
Scope
Date
~
-
Bio & Pharma
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma
South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...
Aug 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Costco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
Aug 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Jul 31, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Apr 23, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung begins new drug development for rare diseases
Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...
Mar 24, 2024 (Gmt+09:00)
-
Bio & Pharma
Reversing age possible in a decade: Harvard Prof. David Sinclair
Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Mar 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Feb 29, 2024 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain releases medical GenAI tech for free
Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...
Feb 20, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Kakao launches AI-based blood sugar management solution
South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...
Feb 01, 2024 (Gmt+09:00)
-
Bio & Pharma
ToolGen gets FDA approval for TGT-001 as ODD
South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...
Dec 18, 2023 (Gmt+09:00)
-
Bio & Pharma
SK C&C to promote AI healthcare for brain diseases
South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...
Nov 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Dong-A ST, UMass to jointly research for gene therapy
South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...
Nov 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Naver-invested ichrogene enters Thai market
South Korea's digital healthcare startup ichrogene, with investment from Naver D2 Startup Factory (D2SF), entered into Thai market. Naver Corp....
Nov 01, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Remsima SC
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare wins Remsima order in France, Italy
South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...
Oct 18, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korean vaccine developer Quratis eyes Iraqi market
South Korean vaccine developer Quratis Inc. on Wednesday announced its signing of a term sheet on the direction and major transaction terms of coope...
Oct 12, 2023 (Gmt+09:00)
-
Bio & Pharma
NGeneBio applies for US patent of early diagnosis tech of dementia
South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...
Sep 14, 2023 (Gmt+09:00)
-
Bio & Pharma
VaxCell Bio's treatment shows promise for advanced liver cancer
South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...
Sep 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to cooperate with Swiss firm Sandoz
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...
Sep 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Yungjin Pharm's new drug candidate gets Fast Track from FDA
South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...
Sep 06, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy
South Korea’s Boryung Corp. on Tuesday said it received approval from the Ministry of Food and Drug Safety for its new compound diabetes drug ...
Sep 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Handok to import treatment for rare autoimmune disorder
South Korean pharmaceutical company Handok Inc. on Wednesday said it signed a deal with Dutch immunology specialist Argenx to sell the latter's Vyvg...
Aug 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong launches GERD treatment Fexuclu in Philippines
South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...
Aug 01, 2023 (Gmt+09:00)
-
Bio & Pharma
Kwangdong to sell exclusively three global rare disease drugs
South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it signed an agreement for securing exclusive sales and distri...
Jul 24, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Biopharm eyes Asia's No.1 spot in radioactive drug market
South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...
Jul 19, 2023 (Gmt+09:00)
-
Bio & Pharma
GI Innovation seeks to license allergy therapy to Japan in 2023
South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...
Jul 17, 2023 (Gmt+09:00)
Latest News
- 1 Bain Capital puts beauty device maker Classys on market
- 2 POSCO International eyes M&A in US natural gas market
- 3 Samsung Galaxy Z Fold Special Edition: slimmest, lightest of its kind
- 4 Hyundai Motor Group six affiliates to strengthen carbon neutrality
- 5 Samsung C&T consortium wins $1.6 bn Turkish highway project